EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

EGFR Antibody Combined With Programmed Death-1 Inhibitor and Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Prospective, Multi-center, Phase I/II Clinical Trial

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

Study Overview

• Status: Recruiting
• Conditions: Recurrent Nasopharynx Carcinoma; Metastatic Nasopharyngeal Carcinoma; Nasopharyngeal Cancinoma (NPC)
• Intervention / Treatment: Radiation: IMRT; Drug: EGFR Antibody; Drug: PD-1 antibody; Drug: Gemcitabine, Cisplatin

• Study Type: Interventional
• Enrollment (Estimated): 148
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Zhao Chong PhD.; Phone Number: 139022061610; Email: zhaochong@sysucc.org.cn
• Study Contact Backup: Name: Miao Jingjing MD.; Phone Number: 13631355201; Email: miaojj@sysucc.org.cn

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China
      • Recruiting
      • Sun yat-sen University Cancer Center
      • Contact: Zhao Chong MD. PhD.; Phone Number: 02087342638; Email: zhaochong@sysucc.org.cn
      • Contact: Miao Jingjing MD.; Phone Number: 86+13631355201; Email: miaojj@sysucc.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with nasopharyngeal carcinoma who have recurred/metastasized after initial treatment or radical treatment;
• Age 18-75, male or female;
• Pathological diagnosis of nasopharyngeal carcinoma;
• ECOG score 0-1;
• Have not previously received any anti-tumor therapy such as radiotherapy, chemotherapy, immunotherapy or biotherapy for recurrence/metastasis;
• No contraindications of chemotherapy, immunotherapy and targeted therapy;
• At least 1 measurable lesion that meets RECIST 1.1 criteria;
• Blood routine examination standards should meet: WBC≥3.0×109/L, ANC≥1.5×109/L, PLT≥100×109/L, HGB≥90g/L (no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulating factors are used to correct);
• Biochemical tests should meet the following criteria: TBIL≤2.0×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance ≥60ml/min (Cockcroft-Gault formula);
• Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as PT is within the intended range of anticoagulant drug use;
• The myocardial enzyme spectra were in the normal range;
• Women of childbearing age must already be using reliable contraception or have had a pregnancy test (serum or urine) within 7 days of enrollment with a negative result and be willing to use an effective method of contraception during the trial and for 3 months after the last anti-PD-1 antibody administration. For male subjects whose partners are women of reproductive age, effective contraception should be used during the trial and within 3 months after the last anti-PD-1 antibody administration;
• The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up;

Exclusion Criteria:

• Patients with recurrence who can be treated with local resection or radiotherapy;
• Known to be allergic to the investigational drug or any excipients thereof, or has had a severe allergic reaction to other monoclonal antibodies;
• Patients have symptoms of central nervous system metastasis such as brain edema and need hormonal intervention;
• Had an active infection or unexplained fever >38.5℃ during screening or prior to the first dose (the investigator determined that the subject's fever due to the tumor could be enrolled);
• Have any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism [may be included after normal hormone replacement therapy]); Patients with vitiligo or complete remission of asthma in childhood without any intervention as adults could be included, but patients with asthma requiring medical intervention with bronchodilators could not be included;
• Have congenital or acquired immunodeficiency (such as HIV), active hepatitis B (HBV-DNA≥103 copy number /ml), or hepatitis C (hepatitis C antibody positive and HCR-RNA above the lower detection limit of analytical methods);
• Previous or co-existing uncured malignancies, except cured basal cell carcinoma of the skin, carcinoma in situ of the cervix and superficial bladder cancer;
• Uncontrolled cardiovascular disease: Grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); Patients with grade III-IV cardiac insufficiency according to NYHA standards, or left ventricular ejection fraction (LVEF) <50% indicated by cardiac color ultrasound; Myocardial infarction within 1 year;
• If the subject has undergone major surgery, the toxic effects and/or complications of the surgical intervention must be fully recovered before treatment is initiated;
• Within 4 weeks prior to the first use of the investigational drug (participants in the follow-up period are counted as the last use of the investigational drug or device) or are currently participating in another clinical study;
• Live vaccine received within 4 weeks prior to the first administration of the investigational drug is allowed to receive inactivated virus vaccine for seasonal influenza by injection, but not live attenuated influenza vaccine for nasal administration;
• Pregnant or lactating women;
• In the investigator's judgment, the subjects had other factors that might have led to their forced discontinuation of the study, such as other serious medical conditions (including mental illness) requiring concomitant treatment, serious abnormalities in laboratory test values, or family or social factors that might have affected the safety of the subjects or the circumstances of the trial data collection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EGFR+PD-1+Chemo	Radiation: IMRT; IMRT for primary lesion; Drug: EGFR Antibody; 6 cycles for combined therapy. Maintenance for 1 year.; Drug: PD-1 antibody; 6 cycles for combined therapy. Maintenance for 1 year.; Drug: Gemcitabine, Cisplatin; 6 cycles for combined therapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival (PFS)	From the date of recruiting to the first occurrence of disease progression as determined according to RECIST v1.1 or death from any cause, whichever occurs first.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	All adverse event or serious adverse event that occurred during the study period according to CTCAE v 5.0.	Up to 16 months
Overall survival (OS)	From the date of recruiting to the date of death from any cause.	1 year
Objective response rate (ORR)	The percentage of patients with CR and PR assessed according to RECIST v1.1.	1 year
Disease control rate (DCR)	The proportion of patients who have achieved complete response, partial response and stable disease according to RECIST v1.1.	1 year
Quality of life (QoL)	Assessed by EQ-5D-5L questionnaire	1 year

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Collaborators: Zhejiang Cancer Hospital; Chongqing University Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang University; Jiangxi Provincial Cancer Hospital; Dongguan People's Hospital; Wuhan TongJi Hospital; First Affiliated Hospital of Guangxi Medical University; Fujian Province Tumor Hospital; Xijing hospital of The fourth military medical university; Liuzhou Workers' Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 9, 2025
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2029

Study Registration Dates

• First Submitted: January 25, 2025
• First Submitted That Met QC Criteria: January 25, 2025
• First Posted (Actual): January 31, 2025

Study Record Updates

• Last Update Posted (Actual): May 11, 2026
• Last Update Submitted That Met QC Criteria: May 6, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: chemotherapy; PD-1 antibody; EGFR antibody
• Additional Relevant MeSH Terms: Stomatognathic Diseases; Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Carcinoma; Otorhinolaryngologic Diseases; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Inorganic Chemicals; Chlorine Compounds; Nitrogen Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Platinum Compounds; Gemcitabine; Cisplatin; spartalizumab
• Other Study ID Numbers: EGFR+PD-1+Chemo for r/mNPC

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No